NHS England will commission emicizumab as prophylaxis in people with severe congenital haemophilia A without factor VIII inhibitors in accordance with the criteria outlined in this policy.
This document provides recommendations on the diagnosis and treatment of tetanus, including: the use of immunoglobulins for the treatment of clinical tetanus the management of tetanus prone wounds revised guidance for classifying tetanus-prone injuries
Revised guidelines from Public Health England that amalgamate previous guidelines on management of clinical tetanus and provide updated advice on laboratory testing and treatment of suspected tetanus cases and management of tetanus prone wounds.
The UK Advisory Panel for Healthcare Workers Infected with Bloodborne Viruses (UKAP) specialist working group has compiled a list of exposure prone procedures (EPPs) and non-EPPs carried out in vascular surgery. Each procedure has been categorised into the level of risk of
This policy document outlines the arrangements for funding of treatment for hereditary factor X deficiency.
This policy document outlines the arrangements for funding of treatment for bleeding episodes in people with acquired haemophilia A.
The blood-borne virus (BBV) opt-out engagement event was led by Public Health England (PHE) working in partnership with NHS England and HMPPS to promote the final implementation stage of BBV opt-out testing for consenting eligible adults in prisons in England. The main